The cancer biotech soared in 2020, jumping up over 1,000% for the year. What will the stock do in 2021?
News & Analysis: Trillium Therapeutics
This promising cancer fighter might sell out this year to cash in on its potential.
When it comes to countering a key trick that cancer plays on the human immune system, this biotech has no equal.
The company's long-term plan is to challenge conventional cancer therapy.
This clinical-stage biotech stock could be a top buyout candidate in 2021.
A decline in the stock price plus positive clinical data equals opportunity.
The micro-cap has shot up an incredible 1,400% this year.
A new CEO and prioritization of research could have more big gains in store for the company
Investors are catching on to the opportunity for this innovative cancer therapy, and so is big pharma.
Adaptimmune Therapeutics and Trillium Therapeutics could be big winners for early shareholders.